$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000117887918000027 Filed on November 05, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q3
Revenue	$32.64M	$20.60M	$10.87M
YoY Change	121.62%	89.41%	410.52%
Cost Of Revenue	$4.340M	$4.310M	$1.790M
YoY Change	66.28%	140.78%	426.47%
Gross Profit	$28.30M	$16.29M	$9.084M
YoY Change	133.5%	79.28%	410.34%
Gross Profit Margin	86.69%	79.07%	83.54%
Selling, General & Admin	$38.77M	$31.87M	$21.65M
YoY Change	35.65%	47.21%	23.91%
% of Gross Profit	137.0%	195.67%	238.3%
Research & Development	$57.22M	$138.2M	$40.64M
YoY Change	24.91%	240.12%	25.2%
% of Gross Profit	202.19%	848.75%	447.39%
Depreciation & Amortization	$1.200M	$1.073M	$851.0K
YoY Change	9.09%	26.09%	-5.44%
% of Gross Profit	4.24%	6.59%	9.37%
Operating Expenses	$97.79M	$172.5M	$284.3M
YoY Change	22.54%	-39.34%	508.55%
Operating Profit	-$69.49M	-$156.2M	-$275.2M
YoY Change	2.67%	-43.25%	512.44%
Interest Expense	-$5.550M	$4.715M	$4.351M
YoY Change	83.17%	8.37%	-510.47%
% of Operating Profit
Other Income/Expense, Net	-$2.040M	-$1.039M	$2.044M
YoY Change	-314.74%	-150.83%	-324.62%
Pretax Income	-$77.07M	-$159.2M	-$276.3M
YoY Change	10.49%	-42.39%	489.1%
Income Tax	$1.110M	-$51.00K	-$164.7M
% Of Pretax Income
Net Earnings	-$78.08M	-$159.2M	-$111.7M
YoY Change	12.82%	42.53%	139.37%
Net Earnings / Revenue	-239.2%	-772.79%	-1026.91%
Basic Earnings Per Share
Diluted Earnings Per Share	-$412.4K	-$841.4K	-$694.5K
COMMON SHARES
Basic Shares Outstanding	189.3M shares	189.1M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$504.2M	$564.4M	$411.5M
YoY Change	40.6%	37.16%	93.74%
Cash & Equivalents	$79.75M	$201.8M	$64.13M
Short-Term Investments	$424.4M	$362.6M	$347.4M
Other Short-Term Assets	$16.60M	$16.20M	$6.200M
YoY Change	-13.99%	161.29%	19.23%
Inventory	$8.390M	$6.311M	$7.300M
Prepaid Expenses
Receivables	$21.96M	$14.19M	$6.000M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$551.1M	$601.0M	$431.0M
YoY Change	40.6%	39.45%	94.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$11.38M	$10.66M	$9.600M
YoY Change	25.52%	11.03%	-5.88%
Goodwill	$197.8M	$197.8M	$197.8M
YoY Change	0.0%	0.0%
Intangibles	$23.00M	$23.00M
YoY Change	0.0%
Long-Term Investments			$15.10M
YoY Change
Other Assets	$6.683M	$6.099M	$4.200M
YoY Change	28.52%	45.21%	133.33%
Total Long-Term Assets	$238.9M	$237.6M	$249.8M
YoY Change	1.61%	-4.9%	-64.13%
TOTAL ASSETS
Total Short-Term Assets	$551.1M	$601.0M	$431.0M
Total Long-Term Assets	$238.9M	$237.6M	$249.8M
Total Assets	$790.0M	$838.6M	$680.8M
YoY Change	25.98%	23.18%	-25.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.606M	$54.30M	$53.70M
YoY Change	-16.03%	1.12%	85.17%
Accrued Expenses
YoY Change
Deferred Revenue	$9.000M
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$86.13M	$65.88M	$68.20M
YoY Change	22.97%	-3.4%	-20.33%
LONG-TERM LIABILITIES
Long-Term Debt	$321.7M	$318.8M	$161.6M
YoY Change	95.92%	97.28%
Other Long-Term Liabilities	$2.853M	$3.029M	$32.10M
YoY Change	21.61%	-90.56%	-89.96%
Total Long-Term Liabilities	$2.853M	$3.029M	$193.7M
YoY Change	21.61%	-98.44%	-39.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$86.13M	$65.88M	$68.20M
Total Long-Term Liabilities	$2.853M	$3.029M	$193.7M
Total Liabilities	$447.0M	$427.6M	$271.1M
YoY Change	63.05%	57.74%	-53.39%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.412B	-$1.334B
YoY Change	32.78%
Common Stock	$1.742B	$1.733B
YoY Change	24.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$342.9M	$411.0M	$409.7M
YoY Change
Total Liabilities & Shareholders Equity	$790.0M	$838.6M	$680.8M
YoY Change	25.98%	23.18%	-25.85%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q3
OPERATING ACTIVITIES
Net Income	-$78.08M	-$159.2M	-$111.7M
YoY Change	12.82%	42.53%	139.37%
Depreciation, Depletion And Amortization	$1.200M	$1.073M	$851.0K
YoY Change	9.09%	26.09%	-5.44%
Cash From Operating Activities	-$60.68M	-$132.8M	-$48.90M
YoY Change	-16.92%	171.49%	19.62%
INVESTING ACTIVITIES
Capital Expenditures	-$1.740M	-$2.690M	-$1.120M
YoY Change	53.98%	140.18%	23.08%
Acquisitions
YoY Change
Other Investing Activities	-$62.06M	$117.2M	-$172.8M
YoY Change	-217.85%	-167.81%	502.06%
Cash From Investing Activities	-$63.80M	$114.5M	-$173.9M
YoY Change	-223.79%	-165.82%	487.37%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$243.0M
YoY Change			506.74%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	360.0K	146.8M	250.2M
YoY Change	-94.75%	-41.32%	531.16%
NET CHANGE
Cash From Operating Activities	-60.68M	-132.8M	-48.90M
Cash From Investing Activities	-63.80M	114.5M	-173.9M
Cash From Financing Activities	360.0K	146.8M	250.2M
Net Change In Cash	-124.1M	128.5M	27.37M
YoY Change	747.81%	369.6%	-188.72%
FREE CASH FLOW
Cash From Operating Activities	-$60.68M	-$132.8M	-$48.90M
Capital Expenditures	-$1.740M	-$2.690M	-$1.120M
Free Cash Flow	-$58.94M	-$130.1M	-$47.78M
YoY Change	-18.04%	172.23%	19.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
	us-gaap	Depreciation Depreciation	3015000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3386000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2049000	USD
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	189289881	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	AMICUS THERAPEUTICS INC
	dei	Entity Small Business EntitySmallBusiness	false
	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	0	USD
	fold	Capital Lease Obligations Incurred Funded By Capital Lease Borrowings CapitalLeaseObligationsIncurredFundedByCapitalLeaseBorrowings	80000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	358998000	USD
CY2018Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	564594000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	437000	USD
CY2018Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashCashEquivalentsAndAvailableforsaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	216000	USD
CY2017Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	358562000	USD
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q3	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	564383000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	4932000	USD
	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-775000	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-12600000	USD
	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-5000000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	637000	USD
	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	681000	USD
	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	-164585000	USD
	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	0	USD
CY2018Q3	fold	Number Of Approved Medicines For Fabry Disease NumberOfApprovedMedicinesForFabryDisease	1	medicine
CY2018Q3	fold	Number Of Gene Therapy Programs NumberOfGeneTherapyPrograms	14	program
CY2018Q3	fold	Number Of Gene Therapy Programs For Batten Disease NumberOfGeneTherapyProgramsForBattenDisease	2	program
CY2018Q3	fold	Number Of Gene Therapy Programs For Neurologic Ls Ds Developed NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped	10	program
CY2017Q3	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	10000000	USD
CY2018Q3	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
	fold	Payment Of Contingent Consideration PaymentOfContingentConsideration	0	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	1067000	USD
	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	2681000	USD
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	53890000	USD
CY2018Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	54330000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9464000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	14189000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12515000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	15483000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-436000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-211000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-1659000	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	-875000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1400758000	USD
CY2018Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1731174000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17067000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7054000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	20873000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7179000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7868000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	62912000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63014000	shares
CY2017Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	465427000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	465427000	USD
CY2018Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017Q4	us-gaap	Assets Assets	627024000	USD
CY2018Q3	us-gaap	Assets Assets	838589000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	391965000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	601034000	USD
CY2017Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	311700000	USD
CY2018Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	365490000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	1000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	5000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	437000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	216000	USD
CY2017Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309938000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	362767000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309502000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	362556000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	362600000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-238622000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	2700000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25400000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	28100000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8400000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8800000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	538000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	17000000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	19300000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	64133000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	187026000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49060000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201827000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	201800000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	49060000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	201827000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187413000	USD
CY2017Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	65577000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51237000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	203830000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-121836000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	152593000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	166989790	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	189254341	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	166989790	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	189254341	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1721000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	1941000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-112973000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-218309000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-158254000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-269522000	USD
CY2017Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	164167000	USD
CY2018Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	172186000	USD
CY2017Q3	us-gaap	Cost Of Revenue CostOfRevenue	1790000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	3626000	USD
CY2018Q3	us-gaap	Cost Of Revenue CostOfRevenue	4310000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	10060000	USD
CY2017Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	295100000	USD
CY2018Q3	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	315300000	USD
CY2017	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2017Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2258000	USD
CY2018Q3	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	2996000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	7750000	USD
CY2018Q3	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	2750000	USD
CY2017Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	14156000	USD
CY2018Q3	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	14156000	USD
	us-gaap	Depreciation Depreciation	2486000	USD
CY2018Q3	us-gaap	Depreciation Depreciation	1073000	USD
CY2018Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	26800000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2018Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6465000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	851000	USD
CY2018Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	88300000	USD
CY2018Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	507400000	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.69
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.44
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.47
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1030000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1146000	USD
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	244250000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	238622000	USD
CY2018Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-1300000	USD
	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-2700000	USD
CY2016Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	269722000	USD
CY2017Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	265350000	USD
CY2017Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	21100000	USD
CY2017Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25400000	USD
CY2018Q3	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	28100000	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	265000	USD
	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2739000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	163000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2739000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2700000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	8000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
CY2017Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2018Q3	us-gaap	Goodwill Goodwill	197797000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	9084000	USD
	us-gaap	Gross Profit GrossProfit	18575000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	16286000	USD
	us-gaap	Gross Profit GrossProfit	48541000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-276349000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-379372000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-159214000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-272018000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-164683000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-164578000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-51000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5182000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1104000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	13037000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3684000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4288000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-344000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1101000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3358000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2633000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2018Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	4351000	USD
	us-gaap	Interest Expense InterestExpense	12820000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	4715000	USD
	us-gaap	Interest Expense InterestExpense	13763000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3662000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3787000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	780000	USD
CY2018Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1899000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	4623000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	6311000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2394000	USD
CY2018Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	2954000	USD
CY2017Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1449000	USD
CY2018Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	1458000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1190000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2702000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2721000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	7371000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	274174000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	427638000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	627024000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	838589000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	70040000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	65880000	USD
CY2017Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27658000	USD
CY2018Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	31096000	USD
CY2017Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309502000	USD
CY2018Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	362556000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	240570000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	450416000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-222775000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57399000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-140661000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-239278000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-111666000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-214794000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-374308000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-159163000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-270914000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	284316000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-156181000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-259294000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5200000	USD
	us-gaap	Operating Expenses OperatingExpenses	392883000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	172467000	USD
	us-gaap	Operating Expenses OperatingExpenses	307835000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-275232000	USD
CY2018Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6099000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-131000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-203000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	244000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	225000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1176000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-3312000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	665000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	1167000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	0	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	59000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Translation Adjustment Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent	168000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-1307000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-3515000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	909000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1392000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2346000	USD
CY2018Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3029000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2044000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4891000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1039000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3593000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	28000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	450358000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	440963000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3398000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4571000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	19316000	USD
CY2018Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16151000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	243036000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294600000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294584000	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	0	USD
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	146622000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	230981000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	388135000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8841000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8492000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3617000	USD
	us-gaap	Profit Loss ProfitLoss	-214794000	USD
	us-gaap	Profit Loss ProfitLoss	-270914000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9062000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10659000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	212000	USD
	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	218000	USD
CY2017Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	40641000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	103502000	USD
CY2018Q3	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	138227000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	213685000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	387000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31867000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1444000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	88435000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	17067000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2177000	USD
CY2018Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2003000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	21647000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	60090000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1063610000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1334141000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10874000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	22201000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	20596000	USD
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	58601000	USD
CY2017Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	0	USD
CY2018Q3	us-gaap	Secured Long Term Debt SecuredLongTermDebt	146622000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	20873000	USD
CY2018Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	20239839	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	352850000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	410951000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	16076000	USD
CY2018Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	13063000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	160796841	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	148963864	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	189162841	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	184606790	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company’s financial instruments that are exposed to concentration of credit risk consist primarily of cash and cash equivalents and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on cash and cash equivalents or its marketable securities.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">. The Company’s accounts receivable at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> have arisen from product sales primarily in the EU. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined and the Company evaluates the creditworthiness of each customer on a regular basis.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001178879-18-000027-index-headers.html	Edgar Link	pending
0001178879-18-000027-index.html	Edgar Link	pending
0001178879-18-000027.txt	Edgar Link	pending
0001178879-18-000027-xbrl.zip	Edgar Link	pending
amicus-09302018x10q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-09302018xex311.htm	Edgar Link	pending
fold-09302018xex312.htm	Edgar Link	pending
fold-09302018xex321.htm	Edgar Link	pending
fold-20180930.xml	Edgar Link	completed
fold-20180930.xsd	Edgar Link	pending
fold-20180930_cal.xml	Edgar Link	unprocessable
fold-20180930_def.xml	Edgar Link	unprocessable
fold-20180930_lab.xml	Edgar Link	unprocessable
fold-20180930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2018 Q4 Form 10-Q Financial Statement

#000117887918000027 Filed on November 05, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2018 Q4 Form 10-Q Financial Statement

#000117887918000027 Filed on November 05, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold